Search

Your search keyword '"Högnäs, Gunilla"' showing total 12 results
Start Over Author "Högnäs, Gunilla"
12 results on '"Högnäs, Gunilla"'

1. Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine

Author

Nurminen, Anssi, Jaatinen, Serafiina, Taavitsainen, Sinja, Högnäs, Gunilla, Lesluyes, Tom, Ansari-Pour, Naser, Tolonen, Teemu, Haase, Kerstin, Koskenalho, Antti, Kankainen, Matti, Jasu, Juho, Rauhala, Hanna, Kesäniemi, Jenni, Nikupaavola, Tiia, Kujala, Paula, Rinta-Kiikka, Irina, Riikonen, Jarno, Kaipia, Antti, Murtola, Teemu, Tammela, Teuvo L., Visakorpi, Tapio, Nykter, Matti, Wedge, David C., Van Loo, Peter, and Bova, G. Steven

Published
2023
Full Text
View/download PDF

2. Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine

Author

Jasu, Juho, Tolonen, Teemu, Antonarakis, Emmanuel S., Beltran, Himisha, Halabi, Susan, Eisenberger, Mario A., Carducci, Michael A., Loriot, Yohann, Van der Eecken, Kim, Lolkema, Martijn, Ryan, Charles J., Taavitsainen, Sinja, Gillessen, Silke, Högnäs, Gunilla, Talvitie, Timo, Taylor, Robert J., Koskenalho, Antti, Ost, Piet, Murtola, Teemu J., Rinta-Kiikka, Irina, Tammela, Teuvo, Auvinen, Anssi, Kujala, Paula, Smith, Thomas J., Kellokumpu-Lehtinen, Pirkko-Liisa, Isaacs, William B., Nykter, Matti, Kesseli, Juha, and Bova, G. Steven

Published
2021
Full Text
View/download PDF

3. Feasibility of Prostate PAXgene Fixation for Molecular Research and Diagnostic Surgical Pathology: Comparison of Matched Fresh Frozen, FFPE, and PFPE Tissues

Author

Högnäs, Gunilla, Kivinummi, Kati, Kallio, Heini M.L., Hieta, Reija, Ruusuvuori, Pekka, Koskenalho, Antti, Kesseli, Juha, Tammela, Teuvo L.J., Riikonen, Jarno, Ilvesaro, Joanna, Kares, Saara, Hirvikoski, Pasi P., Laurila, Marita, Mirtti, Tuomas, Nykter, Matti, Kujala, Paula M., Visakorpi, Tapio, Tolonen, Teemu, and Bova, G. Steven

Published
2018
Full Text
View/download PDF

4. The evolutionary history of lethal metastatic prostate cancer

Author

Gundem, Gunes, Van Loo, Peter, Kremeyer, Barbara, Alexandrov, Ludmil B., Tubio, Jose M. C., Papaemmanuil, Elli, Brewer, Daniel S., Kallio, Heini M. L., Högnäs, Gunilla, Annala, Matti, Kivinummi, Kati, Goody, Victoria, Latimer, Calli, OʼMeara, Sarah, Dawson, Kevin J., Isaacs, William, Emmert-Buck, Michael R., Nykter, Matti, Foster, Christopher, Kote-Jarai, Zsofia, Easton, Douglas, Whitaker, Hayley C., Neal, David E., Cooper, Colin S., Eeles, Rosalind A., Visakorpi, Tapio, Campbell, Peter J., McDermott, Ultan, Wedge, David C., and Bova, Steven G.

Published
2015
Full Text
View/download PDF

7. Integrated clinical, whole genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer

Author

Bova, Stephen G, Kallio, Heini, Annala, Matti, Kivinummi, Kati, Högnäs, Gunilla, Häyrynen, Sergei, Rantapero, Tommi, Kivinen, Virpi, Isaacs, William, Tolonen, Teemu, Nykter, Matti, Visakorpi, Tapio, and University of Tampere

Subjects
Biolääketieteet - Biomedicine, Syöpätaudit - Cancers
Abstract

We report the first combined analysis of whole-genome sequence, detailed clinical history, and transcriptome sequence of multiple prostate cancer metastases in a single patient (A21). Whole-genome and transcriptome sequence was obtained from nine anatomically separate metastases, and targeted DNA sequencing was performed in cancerous and noncancerous foci within the primary tumor specimen removed 5 yr before death. Transcriptome analysis revealed increased expression of androgen receptor (AR)-regulated genes in liver metastases that harbored an AR p.L702H mutation, suggesting a dominant effect by the mutation despite being present in only one of an estimated 16 copies per cell. The metastases harbored several alterations to the PI3K/AKT pathway, including a clonal truncal mutation in PIK3CG and present in all metastatic sites studied. The list of truncal genomic alterations shared by all metastases included homozygous deletion of TP53, hemizygous deletion of RB1 and CHD1, and amplification of FGFR1. If the patient were treated today, given this knowledge, the use of second-generation androgen-directed therapies, cessation of glucocorticoid administration, and therapeutic inhibition of the PI3K/AKT pathway or FGFR1 receptor could provide personalized benefit. Three previously unreported truncal clonal missense mutations (ABCC4 p.R891L, ALDH9A1 p.W89R, and ASNA1 p.P75R) were expressed at the RNA level and assessed as druggable. The truncal status of mutations may be critical for effective actionability and merit further study. Our findings suggest that a large set of deeply analyzed cases could serve as a powerful guide to more effective prostate cancer basic science and personalized cancer medicine clinical trials.

Published
2016

8. Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer

Author

Bova, G. Steven, primary, Kallio, Heini M.L., additional, Annala, Matti, additional, Kivinummi, Kati, additional, Högnäs, Gunilla, additional, Häyrynen, Sergei, additional, Rantapero, Tommi, additional, Kivinen, Virpi, additional, Isaacs, William B., additional, Tolonen, Teemu, additional, Nykter, Matti, additional, and Visakorpi, Tapio, additional

Published
2016
Full Text
View/download PDF

9. Abstract 956: The evolutionary history of lethal metastatic prostate cancer

Author

Gundem, Gunes, primary, Van Loo, Peter, additional, Kremeyer, Barbara, additional, Alexandrov, Ludmil B., additional, Tubio, Jose M.C., additional, Papaemmanuil, Elli, additional, Brewer, Daniel S., additional, Kallio, Heini, additional, Högnäs, Gunilla, additional, Annala, Matti, additional, Kivinummi, Kati, additional, Goody, Victoria, additional, Latimer, Calli, additional, O'Meara, Sarah, additional, Dawson, Kevin J., additional, Isaacs, William, additional, Emmert-Buck, Michael R., additional, Nykter, Matti, additional, Foster, Christopher, additional, Kote-Jarai, Zsofia, additional, Easton, Douglas, additional, Whitaker, Hayley C., additional, Neal, David E., additional, Cooper, Colin S., additional, Eeles, Rosalind A., additional, Visakorpi, Tapio, additional, Campbell, Peter J., additional, McDermott, Ultan, additional, Wedge, David C., additional, and Bova, G. S., additional

Published
2015
Full Text
View/download PDF

10. Abstract 3883: Clonal evolution of a lethal prostate cancer: Integrated whole genome analysis case study

Author

Kallio, Heini M.L., primary, Annala, Matti, additional, Kivinummi, Kati, additional, Högnäs, Gunilla, additional, Gundem, Gunes, additional, Wedge, David C., additional, Van Loo, Peter, additional, Heyn, Holger, additional, Emmert-Buck, Michael R., additional, Isaacs, William B., additional, Esteller, Manel, additional, McDermott, Ultan, additional, Nykter, Matti, additional, Visakorpi, Tapio, additional, and Bova, G. Steven, additional

Published
2015
Full Text
View/download PDF

12. Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer.

Author

Bova GS, Kallio HM, Annala M, Kivinummi K, Högnäs G, Häyrynen S, Rantapero T, Kivinen V, Isaacs WB, Tolonen T, Nykter M, and Visakorpi T

Abstract

We report the first combined analysis of whole-genome sequence, detailed clinical history, and transcriptome sequence of multiple prostate cancer metastases in a single patient (A21). Whole-genome and transcriptome sequence was obtained from nine anatomically separate metastases, and targeted DNA sequencing was performed in cancerous and noncancerous foci within the primary tumor specimen removed 5 yr before death. Transcriptome analysis revealed increased expression of androgen receptor (AR)-regulated genes in liver metastases that harbored an AR p.L702H mutation, suggesting a dominant effect by the mutation despite being present in only one of an estimated 16 copies per cell. The metastases harbored several alterations to the PI3K/AKT pathway, including a clonal truncal mutation in PIK3CG and present in all metastatic sites studied. The list of truncal genomic alterations shared by all metastases included homozygous deletion of TP53, hemizygous deletion of RB1 and CHD1, and amplification of FGFR1. If the patient were treated today, given this knowledge, the use of second-generation androgen-directed therapies, cessation of glucocorticoid administration, and therapeutic inhibition of the PI3K/AKT pathway or FGFR1 receptor could provide personalized benefit. Three previously unreported truncal clonal missense mutations (ABCC4 p.R891L, ALDH9A1 p.W89R, and ASNA1 p.P75R) were expressed at the RNA level and assessed as druggable. The truncal status of mutations may be critical for effective actionability and merit further study. Our findings suggest that a large set of deeply analyzed cases could serve as a powerful guide to more effective prostate cancer basic science and personalized cancer medicine clinical trials.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results